{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T12:55:47Z","timestamp":1780059347747,"version":"3.54.0"},"reference-count":30,"publisher":"IMR Press","issue":"4","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br. J. Hosp. Med. (Lond)"],"abstract":"<jats:p>Aims\/Background: Lambert-Eaton myasthenic syndrome (LEMS) is a rare autoimmune disorder of the neuromuscular junction that is frequently associated with small-cell lung cancer (SCLC). It is characterized by proximal muscle weakness, reduced deep tendon reflexes, and autonomic symptoms, all of which can significantly impair quality of life and complicate oncologic management. Early recognition and timely intervention are crucial to improving clinical outcomes. Case Presentation: We report a case of a 76-year-old man with extensive-stage SCLC and chronic renal insufficiency whose LEMS worsened during durvalumab immunotherapy. Despite continued chemotherapy and immunotherapy, his symptoms progressively worsened. Chemotherapy failed to improve his neurological condition, with subsequent recurrent episodes of muscle weakness. Subsequent administration of intravenous immunoglobulin (IVIG) combined with pyridostigmine led to marked neurological improvement and restoration of muscle strength to grade 5, enabling continuation of antitumor therapy. The patient subsequently received three cycles of second-line lurbinectedin chemotherapy, during which inflammatory responses, anemia, and venous thrombosis developed but were effectively managed with supportive treatment. Results: Following chemotherapy and immunotherapy, the patient\u2019s limb muscle strength recovered to grade 5, followed by recurrent muscle weakness symptoms. Hematologic and biochemical parameters gradually normalized, and inflammatory markers returned to baseline. At discharge, his clinical condition was stable. Conclusion: This case highlights the importance of early recognition and standardized management of paraneoplastic LEMS in enhancing functional recovery and enabling the safe continuation of antitumor therapy.<\/jats:p>","DOI":"10.31083\/bjhm53025","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T10:17:23Z","timestamp":1777457843000},"source":"Crossref","is-referenced-by-count":1,"title":["Lambert-Eaton Myasthenic Syndrome During Immunotherapy in Extensive-Stage Small-Cell Lung Cancer: A Case Report"],"prefix":"10.31083","volume":"87","author":[{"given":"Yunyin","family":"Feng","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Kaihua County Traditional Chinese Medicine Hospital, 324300 Quzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, The Second Affiliated Hospital, Zhejiang University School of Medicine, 310000 Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1989-7682","authenticated-orcid":true,"given":"Liren","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, The Second Affiliated Hospital, Zhejiang University School of Medicine, 310000 Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Lipka AF, Verschuuren JJGM. Lambert-Eaton myasthenic syndrome. Handbook of Clinical Neurology. 2024; 200: 307\u2013325.","DOI":"10.1016\/B978-0-12-823912-4.00012-8"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"El-Wahsh S, Reddel S. Lambert Eaton Myasthenic Syndrome. International Review of Neurobiology. 2025; 182: 227\u2013251.","DOI":"10.1016\/bs.irn.2025.04.027"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Briggs SE, Gozzard P, Talbot DC. The association between Lambert-Eaton myasthenic syndrome and small cell lung carcinoma. ImmunoTargets and Therapy. 2013; 2: 31\u201337.","DOI":"10.2147\/ITT.S31971"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Titulaer MJ, Wirtz PW, Willems LNA, van Kralingen KW, Smitt PAES, Verschuuren JJGM. Screening for small-cell lung cancer: a follow-up study of patients with Lambert-Eaton myasthenic syndrome. Journal of Clinical Oncology. 2008; 26: 4276\u20134281.","DOI":"10.1200\/JCO.2008.17.5133"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Oda Y, Tsubouchi H, Ishii N, Kitamura A, Moriyama E, Mitsutome E, et al. A rare case of concomitant Lambert-Eaton myasthenic syndrome and syndrome of inappropriate antidiuretic hormone secretion in a patient with small cell lung carcinoma. Respiratory Medicine Case Reports. 2023; 46: 101930.","DOI":"10.1016\/j.rmcr.2023.101930"},{"key":"ref6","unstructured":"Jayarangaiah A, Lui F, Theetha Kariyanna P. Lambert-Eaton Myasthenic Syndrome. StatPearls Publishing: Treasure Island (FL). 2023."},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Qin K, Gay CM, Byers LA, Zhang J. The current and emerging immunotherapy paradigm in small-cell lung cancer. Nature Cancer. 2025; 6: 954\u2013966.","DOI":"10.1038\/s43018-025-00992-5"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019; 394: 1929\u20131939.","DOI":"10.1016\/S0140-6736(19)32222-6"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Ramos-Casals M, Brahmer JR, Callahan MK, Flores-Ch\u00e1vez A, Keegan N, Khamashta MA, et al. Immune-related adverse events of checkpoint inhibitors. Nature Reviews. Disease Primers. 2020; 6: 38.","DOI":"10.1038\/s41572-020-0160-6"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology. 2018; 36: 1714\u20131768.","DOI":"10.1200\/JCO.2017.77.6385"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Gagnier JJ, Kienle G, Altman DG, Moher D, Sox H, Riley D, et al. The CARE guidelines: consensus-based clinical case reporting guideline development. Journal of Medical Case Reports. 2013; 7: 223.","DOI":"10.1186\/1752-1947-7-223"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Baine MK, Hsieh MS, Lai WV, Egger JV, Jungbluth AA, Daneshbod Y, et al. SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization. Journal of Thoracic Oncology. 2020; 15: 1823\u20131835.","DOI":"10.1016\/j.jtho.2020.09.009"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Campetella L, Papi C, Sabatelli E, Marini S, Iorio R. Real-world application of the updated diagnostic criteria for paraneoplastic neurological syndromes. Journal of Neuroimmunology. 2022; 372: 577972.","DOI":"10.1016\/j.jneuroim.2022.577972"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Schoser B, Eymard B, Datt J, Mantegazza R. Lambert-Eaton myasthenic syndrome (LEMS): a rare autoimmune presynaptic disorder often associated with cancer. Journal of Neurology. 2017; 264: 1854\u20131863.","DOI":"10.1007\/s00415-017-8541-9"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Meisel A, Sieb JP, Le Masson G, Postila V, Sacconi S. The European Lambert-Eaton Myasthenic Syndrome Registry: Long-Term Outcomes Following Symptomatic Treatment. Neurology and Therapy. 2022; 11: 1071\u20131083.","DOI":"10.1007\/s40120-022-00354-8"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Alhammad RM, Alshamlan Y, Alneseyan R, Al-Harbi TM, Alhijab A, Alanazy MH. Clinical presentations, electrophysiologic features, and long-term follow-up in Lambert-Eaton myasthenic syndrome: a series of six patients. Frontiers in Neurology. 2024; 15: 1525155.","DOI":"10.3389\/fneur.2024.1525155"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Titulaer MJ, Maddison P, Sont JK, Wirtz PW, Hilton-Jones D, Klooster R, et al. Clinical Dutch-English Lambert-Eaton Myasthenic syndrome (LEMS) tumor association prediction score accurately predicts small-cell lung cancer in the LEMS. Journal of Clinical Oncology. 2011; 29: 902\u2013908.","DOI":"10.1200\/JCO.2010.32.0440"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Zhang L, Fan S, Wang J, Ren H, Guan H. Antibody-positive paraneoplastic neurological syndromes associated with immune checkpoint inhibitors: a systematic review. Journal of Neurology. 2025; 272: 249.","DOI":"10.1007\/s00415-025-12992-7"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Kunii E, Owaki S, Yamada K, Yoshihara M, Yamaba Y, Takakuwa O, et al. Lambert-Eaton Myasthenic Syndrome Caused by Atezolizumab in a Patient with Small-cell Lung Cancer. Internal Medicine. 2022; 61: 1739\u20131742.","DOI":"10.2169\/internalmedicine.8387-21"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Yamazoe M, Hatakeyama T, Furukawa K, Kato K, Horiuchi K. Atezolizumab-Induced Lambert-Eaton Myasthenic Syndrome in a Patient With Small-Cell Lung Cancer. Cureus. 2023; 15: e33557.","DOI":"10.7759\/cureus.33557"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Machiyama H, Minami S. Durvalumab for Extensive-Stage of Small-Cell Lung Cancer With Lambert-Eaton Myasthenic Syndrome. Journal of Medical Cases. 2023; 14: 71\u201375.","DOI":"10.14740\/jmc4043"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Takigawa Y, Watanabe H, Omote Y, Kurihara S, Inoue T, Fujiwara M, et al. Lambert-Eaton Myasthenic Syndrome Recurrence Induced by Pembrolizumab in a Patient with Non-small-cell Lung Cancer. Internal Medicine. 2023; 62: 1055\u20131058.","DOI":"10.2169\/internalmedicine.0072-22"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Pascuzzi RM, Bodkin CL. Myasthenia Gravis and Lambert-Eaton Myasthenic Syndrome: New Developments in Diagnosis and Treatment. Neuropsychiatric Disease and Treatment. 2022; 18: 3001\u20133022.","DOI":"10.2147\/NDT.S296714"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Wiendl H, Abicht A, Chan A, Della Marina A, Hagenacker T, Hekmat K, et al. Guideline for the management of myasthenic syndromes. Therapeutic Advances in Neurological Disorders. 2023; 16: 17562864231213240.","DOI":"10.1177\/17562864231213240"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Oh SJ. Amifampridine to treat Lambert-Eaton myasthenic syndrome. Drugs of Today. 2020; 56: 623\u2013641.","DOI":"10.1358\/dot.2020.56.10.3137144"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Sasaoka T, Ujiie H, Nishie W, Iwata H, Ishikawa M, Higashino H, et al. Intravenous IgG Reduces Pathogenic Autoantibodies, Serum IL-6 Levels, and Disease Severity in Experimental Bullous Pemphigoid Models. The Journal of Investigative Dermatology. 2018; 138: 1260\u20131267.","DOI":"10.1016\/j.jid.2018.01.005"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Coutinho AE, Chapman KE. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Molecular and Cellular Endocrinology. 2011; 335: 2\u201313.","DOI":"10.1016\/j.mce.2010.04.005"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Trigo J, Subbiah V, Besse B, Moreno V, L\u00f3pez R, Sala MA, et al. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. The Lancet. Oncology. 2020; 21: 645\u2013654.","DOI":"10.1016\/S1470-2045(20)30068-1"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Tang J, Wang T, Wu H, Bao X, Xu K, Ren T. Efficacy and toxicity of lurbinectedin in subsequent systemic therapy of extensive-stage small cell lung cancer: a meta-analysis. BMC Cancer. 2024; 24: 1351.","DOI":"10.1186\/s12885-024-13104-w"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Dohrn MF, Sch\u00f6ne U, K\u00fcppers C, Christen D, Schulz JB, Gess B, et al. Immunoglobulins to mitigate paraneoplastic Lambert Eaton Myasthenic Syndrome under checkpoint inhibition in Merkel cell carcinoma. Neurological Research and Practice. 2020; 2: 52.","DOI":"10.1186\/s42466-020-00099-5"}],"container-title":["British Journal of Hospital Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/BJHM\/87\/4\/10.31083\/BJHM53025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T10:18:23Z","timestamp":1777457903000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/BJHM\/87\/4\/10.31083\/BJHM53025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"alternative-id":["S1750-8460(26)02640-0"],"URL":"https:\/\/doi.org\/10.31083\/bjhm53025","relation":{},"ISSN":["1750-8460","1759-7390"],"issn-type":[{"value":"1750-8460","type":"print"},{"value":"1759-7390","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]},"article-number":"53025"}}